Pooja Tiwari, Uma K Saikia, Abhamoni Baro, Ashok K Bhuyan
{"title":"巨泌乳素瘤的临床特征和对药物治疗的反应","authors":"Pooja Tiwari, Uma K Saikia, Abhamoni Baro, Ashok K Bhuyan","doi":"10.4103/ijem.ijem_283_23","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The presentation of macroprolactinomas and response to treatment may vary according to age, sex and tumour characteristics. To analyse clinical phenotype, biochemical and radiological characteristics of macroprolactinomas presenting to a tertiary care centre. A retrospective observational study from January 2018 to December 2022.</p><p><strong>Methods: </strong>Thirty diagnosed cases (18 females, 12 males) of macroprolactinomas were included and followed up for one year.</p><p><strong>Results: </strong>The most common presentation was headache (73%), visual disturbances (50%), galactorrhoea (33.3%) and loss of libido (26.6%) along with menstrual cycle disturbances (94%), and infertility (55%) in females. Duration of symptoms (2.22 ± 2.87 vs 4.61 ± 3.4 years), tumour size (4.8 ± 2.09 vs 2.75 ± 1.24 cm) and prolactin levels (5153.5 ± 4755.3 vs 1803.5 ± 3785.5 ng/ml) were different significantly between males and females. Good response to medical therapy was observed in 84% of the treatment-naive patients.</p><p><strong>Conclusion: </strong>Macroprolactinomas in males present with shorter duration of symptoms, larger size, higher prolactin levels and more resistant tumours, emphasizing the need for early diagnosis and aggressive management. Medical therapy remains the treatment of choice irrespective of gender.</p>","PeriodicalId":13353,"journal":{"name":"Indian Journal of Endocrinology and Metabolism","volume":"28 3","pages":"268-272"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11288516/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clinical Characteristics of Macroprolactinomas and Response to Medical Therapy.\",\"authors\":\"Pooja Tiwari, Uma K Saikia, Abhamoni Baro, Ashok K Bhuyan\",\"doi\":\"10.4103/ijem.ijem_283_23\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The presentation of macroprolactinomas and response to treatment may vary according to age, sex and tumour characteristics. To analyse clinical phenotype, biochemical and radiological characteristics of macroprolactinomas presenting to a tertiary care centre. A retrospective observational study from January 2018 to December 2022.</p><p><strong>Methods: </strong>Thirty diagnosed cases (18 females, 12 males) of macroprolactinomas were included and followed up for one year.</p><p><strong>Results: </strong>The most common presentation was headache (73%), visual disturbances (50%), galactorrhoea (33.3%) and loss of libido (26.6%) along with menstrual cycle disturbances (94%), and infertility (55%) in females. Duration of symptoms (2.22 ± 2.87 vs 4.61 ± 3.4 years), tumour size (4.8 ± 2.09 vs 2.75 ± 1.24 cm) and prolactin levels (5153.5 ± 4755.3 vs 1803.5 ± 3785.5 ng/ml) were different significantly between males and females. Good response to medical therapy was observed in 84% of the treatment-naive patients.</p><p><strong>Conclusion: </strong>Macroprolactinomas in males present with shorter duration of symptoms, larger size, higher prolactin levels and more resistant tumours, emphasizing the need for early diagnosis and aggressive management. Medical therapy remains the treatment of choice irrespective of gender.</p>\",\"PeriodicalId\":13353,\"journal\":{\"name\":\"Indian Journal of Endocrinology and Metabolism\",\"volume\":\"28 3\",\"pages\":\"268-272\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11288516/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Endocrinology and Metabolism\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/ijem.ijem_283_23\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Endocrinology and Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ijem.ijem_283_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/26 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
导言大泌乳素瘤的表现和对治疗的反应可能因年龄、性别和肿瘤特征而异。目的:分析在一家三级医疗中心就诊的大乳头泌乳素瘤的临床表型、生化和放射学特征。2018年1月至2022年12月的回顾性观察研究:纳入30例确诊的大泌乳素瘤病例(女性18例,男性12例),并随访一年:最常见的表现是头痛(73%)、视力障碍(50%)、白带增多(33.3%)和性欲减退(26.6%),女性患者还伴有月经周期紊乱(94%)和不孕(55%)。男性和女性的症状持续时间(2.22 ± 2.87 年 vs 4.61 ± 3.4 年)、肿瘤大小(4.8 ± 2.09 cm vs 2.75 ± 1.24 cm)和催乳素水平(5153.5 ± 4755.3 vs 1803.5 ± 3785.5 ng/ml)差异显著。84%的患者对药物治疗反应良好:结论:男性巨泌乳素瘤的症状持续时间较短、体积较大、泌乳素水平较高、抗药性较强,因此需要早期诊断和积极治疗。无论男女,药物治疗仍是首选治疗方法。
Clinical Characteristics of Macroprolactinomas and Response to Medical Therapy.
Introduction: The presentation of macroprolactinomas and response to treatment may vary according to age, sex and tumour characteristics. To analyse clinical phenotype, biochemical and radiological characteristics of macroprolactinomas presenting to a tertiary care centre. A retrospective observational study from January 2018 to December 2022.
Methods: Thirty diagnosed cases (18 females, 12 males) of macroprolactinomas were included and followed up for one year.
Results: The most common presentation was headache (73%), visual disturbances (50%), galactorrhoea (33.3%) and loss of libido (26.6%) along with menstrual cycle disturbances (94%), and infertility (55%) in females. Duration of symptoms (2.22 ± 2.87 vs 4.61 ± 3.4 years), tumour size (4.8 ± 2.09 vs 2.75 ± 1.24 cm) and prolactin levels (5153.5 ± 4755.3 vs 1803.5 ± 3785.5 ng/ml) were different significantly between males and females. Good response to medical therapy was observed in 84% of the treatment-naive patients.
Conclusion: Macroprolactinomas in males present with shorter duration of symptoms, larger size, higher prolactin levels and more resistant tumours, emphasizing the need for early diagnosis and aggressive management. Medical therapy remains the treatment of choice irrespective of gender.
期刊介绍:
The Indian Journal of Endocrinology and Metabolism (IJEM) aims to function as the global face of Indian endocrinology research. It aims to act as a bridge between global and national advances in this field. The journal publishes thought-provoking editorials, comprehensive reviews, cutting-edge original research, focused brief communications and insightful letters to editor. The journal encourages authors to submit articles addressing aspects of science related to Endocrinology and Metabolism in particular Diabetology. Articles related to Clinical and Tropical endocrinology are especially encouraged. Sub-topic based Supplements are published regularly. This allows the journal to highlight issues relevant to Endocrine practitioners working in India as well as other countries. IJEM is free access in the true sense of the word, (it charges neither authors nor readers) and this enhances its global appeal.